Transcriptome analysis of Candida auris treated with tunicamycin
Ontology highlight
ABSTRACT:
INSTRUMENT(S): DNBSEQ-T7
ORGANISM(S): Candida auris
SUBMITTER: FENG YANG
PROVIDER: E-MTAB-16877 | biostudies-arrayexpress |
REPOSITORIES: biostudies-arrayexpress
Similar Datasets
Project description:C. auris strain B12037 was exposed to tunicamycin. Transcriptomes of three mutants, TJ101 (#10), TJ107 (#16) and TJ110 (#19) were compared to parent. Cells were grown in YPD broth from OD600=0.1 till 1.0, then cells pellets were harvested.
2026-04-25 | E-MTAB-16883 | biostudies-arrayexpress
Project description:Olfactory ensheathing cells are one of the few central nervous system regenerative cells discovered so far. It is characterized by its lifelong nerve regeneration function, and it can also release a variety of neurotrophic factors and neural adhesion molecules. It is considered to be the glial cell with the strongest myelination ability. Olfactory ensheathing cells and Schwann cells have phenotypes in common, they can promote axon regeneration(R. Doucette, 1995). Olfactory ensheathing cells have the characteristics of Schwann cells and astrocytes, but the overall performance tends to be the former, which has two unique characteristics. First, it exists not only in the peripheral nerves (Schwann cells), but also in the central nervous system (astroglia); second, the olfactory mucosa has the ability to regenerate life-long, including human olfactory ensheathing cells(J. C. Bartolomei and C. A. Greer, 2000). Regeneration is a process in which olfactory ensheathing cells participate in efficient regulation, although the specific mechanism is not yet clear. Olfactory ensheathing cells are different from astrocytes and Schwann cells, but at the same time have the characteristics of these two cells(S. C. Barnett, 2004), like Schwann cells help axon growth, but more than Schwann cells It can make axons grow long distances, that is, it has stronger migration(A. Ramon-Cueto et al., 1998); there are also astrocytes that have a nutritional effect on the survival of neurons and the growth of axons, but olfactory ensheathing cells can also wrap neurons forms myelin sheath to support the growth of nerve processes(R. Devon and R. Doucette, 1992; J. Gu et al., 2019). There are two characteristics that make olfactory ensheathing cells the best choice for the treatment of neurological diseases(S. C. Chiu et al., 2009; J. Kim et al., 2018; M. Abdel-Rahman et al., 2018). Olfactory ensheathing cells are gradually used to treat spinal cord injuries and have shown amazing effects(J. C. Bartolomei and C. A. Greer, 2000; K. J. Liu et al., 2010; R. Yao et al., 2018). Olfactory ensheathing cells that have been used in research are usually derived from the olfactory bulb(E. H. Franssen et al., 2007), but it is easier to obtain olfactory ensheathing cells from the olfactory mucosa in clinical practice(M. Ryszard et al., 2006), so the difference between the olfactory ensheathing cells from the olfactory bulb and the olfactory mucosa There are more and more studies(B. M. U. et al., 2007), and previous studies have shown that they not only have many similar functions, but also have many differences(M. W. Richter et al., 2005; L. Wang et al., 2014; K. E. Smith et al., 2020). Because olfactory ensheathing cells derived from the olfactory bulb are not easy to obtain, olfactory ensheathing cells derived from the olfactory mucosa have become the focus of attention. Although we know that olfactory ensheathing cells from two sources have nerve repair functions, it is not clear why the two different sources of olfactory ensheathing cells have different therapeutic effects. Nicolas G. once studied that the genetic difference between the two cells and found that there are many genes related to wound repair and nerve regeneration(G. Nicolas et al., 2010). We have reason to guess that olfactory ensheathing cells from these two sources will also have a large difference in protein level. Our research group wants to use the current mature transcriptome and proteomic sequencing technologies to explore the difference between olfactory ensheathing cells from the olfactory bulb and olfactory mucosa, and explain why the two sources of olfactory ensheathing cells shows different therapeutic effects, hope to provide a new theoretical basis for future clinical treatment.
2022-02-16 | PXD024046 | Pride
Project description:The observation that human Pluripotent Stem Cells (hPSCs) may acquire non-random genetic changes during prolonged culture is a major concern for their use in regenerative medicine and disease modelling. The mechanisms through which genetically variant cells are selected for in culture remain poorly characterized. We have shown that the dominance of variant hPSCs with enhanced growth rates is enhanced through competitive interactions resulting in the elimination of the slower growing loser population. This experiment compares the gene expression of winner (H7v1,12,17q,20q-GFP) and loser (H7v1q) grown either in separate culture or competitively in co-culture together.
2021-03-18 | E-MTAB-10193 | biostudies-arrayexpress
Project description:Decipher the direct and indirect targets of human miR-6762-5p by doxycyclin-inducible expression in HeLa cells
2024-12-01 | E-MTAB-14115 | biostudies-arrayexpress
Project description:Exosomes derived from human adipose tissue mesenchymal stem cells (hASCs) have demonstrated anti-inflammatory and rejuvenating properties, making them promising agents for neurochemical intervention. However, their transcriptomic impact on neuronal cells remains largely unexplored. To address this research question, we applied high-throughput mRNA sequencing analysis. As an in vitro model, CNS mouse-derived CAD cells were exposed to D-galactose (DG) to trigger molecular responses and were used to evaluate the efficacy of the isolated exosomes. Illumina-based mRNA sequencing has allowed expression profiling of more than 270000 genes. Comparative transcriptomic profiling revealed 3,951 differentially expressed genes (DEGs) associated with DG-induced cells and 3,091 DEGs modulated by hASC-exosome treatment.In the presence of hASC-derived exosomes, many DEGs (1,948) were downregulated. A set of genes involved in the inflammatory response and regulated by hASC-exosomes was identified. Our study provides transcriptomic evidence supporting the regulatory role of hASC-derived exosomes in attenuating the expression of inflammatory and neurodegenerative markers, positioning them as potential candidates for antiaging neurotherapeutics.
2025-10-17 | E-MTAB-15753 | biostudies-arrayexpress
Project description:Investigate the effect of silencing ABCB8 on the transcriptional profile of HUVECs
2025-11-15 | E-MTAB-15027 | biostudies-arrayexpress
Project description:We have generated CRISPR edited versions of hESC line MShef11 to produce MFN2 R94Q/+ and MFN2 R94Q/R94Q lines as a model for Charcot Marie Tooth Disease (CMT) 2A. This were differentiated to limb innervating motor neurons, the predominantly affected cell time in CMT2A and RNA was examined to investigate differences in cell lines.
2022-07-28 | E-MTAB-10831 | biostudies-arrayexpress
Project description:Effects of JMY on gene expression in U2OS under etoposide treatment
2023-04-20 | E-MTAB-12059 | biostudies-arrayexpress
Project description:We investigated the transcriptome profile of HEK293T cells transfected with a plasmid encoding 9J10, a peptide isolated in a phenotypic screen from a library of peptides derived from bacterial and archaeal genomes. The peptide was identified in a screen for FOXO3a reactivation and has been shown to interact with 14-3-3 proteins and induce relocalisation of FOXO3a from the cytoplasm to the nucleus. A peptide with a single amino acid mutation does not interact with 14-3-3 and was included as a control. A constitutively active FOXO3a mutant was also included as a control.
2021-05-28 | E-MTAB-10161 | biostudies-arrayexpress
Project description:Background: Inducing apoptosis of autoreactive lymphocytes is part of the therapeutic strategy for Crohn’s disease (CD) patients. Failure to respond to medical therapies upon inflammatory bowel disease could result from insufficient apoptosis. To date there are no useful molecular factors for the prediction of clinical relapse. Study Aims: Characterization of the BCL-2 family-related risk of therapy resistance and verifying its usefulness as parameter for the prediction of clinical relapse could be helpful in deciding which medical therapy to recommend. The project is directly targeted to develop rapidly therapeutic improvement for patients with IBD. A long-term goal is the development of new therapeutic options for the treatment of IBD via a physiologic homeostasis and turnover of lymphocytes. Study Design: We propose to characterize the BCL-2 family-related risk of therapy resistance and its usefulness as parameter for the prediction of clinical relapse upon medical therapy. Samples will be used for next generation sequencing, qPCR, WB, immunohistochemistry and immunofluorescence. The hypothesis is considered confirmed if expression of BCL-2 family members in human peripheral blood is significantly changed between patient groups and correlates with the number of lymphocyte subpopulations.
2018-05-14 | E-MTAB-6739 | biostudies-arrayexpress